Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer-Reference-Cited by-同舟云学术

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

Published:2008-09-01 Issue:5 Volume:113 Page:975-984
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Higano Celestia S.,Corman John M.,Smith David C.,Centeno Arthur S.,Steidle Christopher P.,Gittleman Marc,Simons Jonathan W.,Sacks Natalie,Aimi Junko,Small Eric J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Demonstration of a rational strategy for human prostate cancer gene therapy;Sanda;J Urol.,1994

2. Cancer vaccines: moving beyond current paradigms;Schlom;Clin Cancer Res.,2007

3. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer;Simons;Clin Cancer Res.,2006

4. Placebo-controlledphase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer;Small;J Clin Oncol.,2006

5. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells;Lin;Urol Oncol.,2006

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial;Nature Medicine;2024-06

2. Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers;Nature Reviews Urology;2024-04-16

3. Siglec-15 Antibody-GM-CSF Chimera Suppresses Tumor Progression via Reprogramming Tumor-Associated Macrophages;2024

4. Inmunoterapia en cáncer de próstata: fundamentos y oportunidades para su aplicación en la clínica;Gaceta Mexicana de Oncolog�a;2023-09-07

5. Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy;International Journal of Molecular Sciences;2023-07-29